Alzheimer Society of Canada Survey – Leqembi (lecanemab) and donanemab |
Background
The Alzheimer Society of Canada is looking for people living with Alzheimer's disease or people with mild cognitive impairment (MCI) due to Alzheimer's disease to share their experiences with the condition, the health-care system and treatments.
New disease-modifying medicines may become available in Canada, and we want to provide input to support decisions to include these medicines in publicly funded drug plans. In this survey, we also seek input from people who have been treated with Leqembi (lecanemab) and/or donanemab.
Health Canada will be reviewing the use of Leqembi (lecanemab) and donanemab to treat early stage Alzheimer's disease and mild cognitive impairment due to Alzheimer’s disease. The Alzheimer Society will be making a submission to Canada's Drug Agency to ensure that the voices of people with lived experience are represented and considered during this review process. Canada’s Drug Agency will use this submission and other information to make a recommendation about whether Canada’s publicly funded drug plans should pay for Leqembi (lecanemab) and/or donanemab if it becomes available on the Canadian market.
The purpose of this survey is for you to share your experiences with Alzheimer’s disease and mild cognitive impairment. Additionally, if applicable, this survey is an opportunity for you to share your experiences receiving treatment with Leqembi (lecanemab) and/or donanemab.